This trial is evaluating whether nab-paclitaxel will improve 9 primary outcomes and 33 secondary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of Up to 28 days.
This trial requires 369 total participants across 2 different treatment groups
This trial involves 2 different treatments. Nab-paclitaxel is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The best form of systemic therapy for patients with this type of cancer is debated in the scientific literature. Findings from a recent study of clinical trials evaluating the efficacy of different therapies must be considered in the management of patients with this type of cancer in routine medical practice, as well as in future trials regarding the treatment of unresectable disease.
Adenocarcinoma typically consists of glandular structures with a mucus lining, and can spread in more limited ways than a carcinoma. There are many subtypes of adenocarcinoma and the terminology is always confusing. If adenocarcinoma is suspected, a biopsy is recommended, and a microscopic examination may discover a number of the potential subtypes.
Overall, there was a similar utilization of therapies across racial groups in these selected studies. The utilization of chemotherapy was higher in patients receiving adjuvant therapies, whereas the use of adjuvant endocrine therapy was higher in patients who had undergone a hysterectomy. Despite these differences in therapy utilization, survival was comparable across racial groups in these selected studies. A better understanding of the pharmacologic treatments for colon cancer should provide support for a better quality of care provided to patients with this disease.
Most symptoms of adenocarcinoma of the oesophagus occur only in advanced disease or are non-specific. It is therefore difficult to identify clinically by signs or symptoms alone. The best method of diagnosis is usually by a flexible endoscope and biopsy, but the only definitive method is surgery.
Findings from a recent study of this investigation did not support a genetic component for adenocarcinoma in patients with acrolein-induced leukoplakia. Rather, they are consistent with a mechanical mechanism in which acrolein's cytotoxic action damages the crypt cells and then induces proliferation and transformation of acrolein-treated cells to adenocarcinoma. This is supported by the observation that no patient with acrolein-induced leukoplakia developed adenocarcinoma anywhere other than the area of leukoplakia.
Most adenocarcinomas can be cured. A cure can be achieved in about 80% of women and about 62% of men with early-stage disease. The chance of cure is enhanced if, among women, the disease has not metastasized (stage IVB) or the disease cannot spread through the circulatory system (stage IVC1). This is especially important if lymph nodes and/or the pelvis are involved. In women with disseminated disease, the chance of cure is still very low, even after the spread-out of the disease. For all patients, about 25% do, however, experience spontaneous disease regression.
Adenocarcinoma cases occur more seldom in non-Hispanic whites than non-Hispanic blacks. The incidence of adenocarcinoma is increasing, especially among white men. Adenocarcinoma may be an underrecognized and important complication among black male smokers.
Given that nab-paclitaxel is used alone or in combination with other anticancer drugs in routine clinical practice, the most common combinations of drugs are carboplatin-paclitaxel, capecitabine-paclitaxel, nab-paclitaxel + gemcitabine, nab-paclitaxel + erlotinib, and nab-paclitaxel + sorafenib.
Nab-paclitaxel is efficacious in the treatment of patients with [metastatic breast cancer](https://www.withpower.com/clinical-trials/metastatic-breast-cancer) and is an important addition in the treatment of breast cancer and multiple myeloma. Findings from a recent study may be the largest single-center experience in examining the use of nab-paclitaxel for the treatment of taxane-refractory metastatic breast cancer. As a result of our study, nab-paclitaxel should be included in the routine chemotherapy of metastatic breast cancer patients.
There is no association between any of the predisposing genes and familial adenocarcinoma of the colon. The genetic heterogeneity of colon cancer should be taken into account for molecular genetic studies on prognostic or therapeutic targets.
nab-paclitaxel seems to be well tolerated in the treatment of patients with metastatic adenocarcinomas. These patients should be followed up for signs of toxicity because nab-paclitaxel is a new treatment approach with no confirmed long-term toxicity.